⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

September 2, 2025Open Access

Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Evan J. Lipson Sonia Dolfi Hao Tang Hussein A. Tawbi Francisco Medina-Soto Erika Castillo Gutiérrez Piotr Rutkowski Helen Gogas E. de Eusebio Murillo Paolo A. Ascierto Keyur Desai Michele Maio Korey Demers Antonella Mazzei Sarah Keidel Karen Miller-Moslin Jia Xin Yu F. Stephen Hodi Dirk Schadendorf Georgina V. Long Charlie Garnett‐Benson

View Full Paper

Ask AI

Bookmark

Share

Key Points

PFS was notably different between patients with low and medium LAG-3 tumors, indicating potential treatment variability.
Patients treated with NIVO plus RELA showed differing outcomes based on LAG-3/CD8+ tumor levels, suggesting biomarker utility.
Stratified analyses revealed insights into the different responses to immunotherapy in advanced melanoma patients, shaping future treatment routes.
Findings may support the incorporation of LAG-3 as a biomarker for patient stratification in advanced melanoma treatments.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Analysis reveals PFS variations according to LAG-3 stratification in melanoma patients receiving relatlimab therapy.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lipson et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f551 https://doi.org/10.1158/1078-0432.30029461

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
2Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
3Supplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
4Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
5Data from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
6Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
7Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
8Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025